Physician profile
Ambili George
NPI 1407503873
$1,231.22
in general payments reported to CMS, 2019-2025
20 companies · $652 in 2025
The $652 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $166 · 2024: $413 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.74 | 2024 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $110.66 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.28 | 2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $103.32 | 2023 | Terlivaz |
| Insmed, INC. | $97.67 | 2025 | Arikayce |
| Astellas Pharma US INC | $83.06 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $80.10 | 2023-2024 | |
| Exact Sciences Corporation | $78.97 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $66.95 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $60.39 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $50.00 | 2025 | Neffy |
| Smith+Nephew, INC. | $47.11 | 2025 | Collagenase Santyl |
| Madrigal Pharmaceuticals | $40.28 | 2025 | Rezdiffra |
| Novo Nordisk INC | $39.98 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $28.73 | 2024 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.98 | 2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $22.52 | 2025 | Hillrom - Monarch Airway Clearance System |
| Medicomp INC | $21.91 | 2024 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $16.15 | 2025 | Inceptiv |
| Glaxosmithkline, LLC. | $15.42 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambili George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.